shutterstock_613544495-atmosphere1
Atmosphere1 / Shutterstock.com
25 June 2019Big Pharma

Fed Circuit sides with Merck in antifungal treatment dispute

A US court has upheld a decision that eight claims of one of Mayne Pharma’s patents are unpatentable for obviousness over prior art after a validity challenge was brought by a subsidiary of Merck & Co.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
22 May 2019   Merck has announced plans to acquire Peloton Therapeutics, a clinical-stage biopharmaceutical company, in a $1.05 billion bid to boost its oncology pipeline.
Big Pharma
31 October 2019   The US Court of Appeals for the Federal Circuit has delivered a blow for Merck in a patent infringement dispute against Gilead, upholding one of its patents as invalid.

More on this story

Americas
22 May 2019   Merck has announced plans to acquire Peloton Therapeutics, a clinical-stage biopharmaceutical company, in a $1.05 billion bid to boost its oncology pipeline.
Big Pharma
31 October 2019   The US Court of Appeals for the Federal Circuit has delivered a blow for Merck in a patent infringement dispute against Gilead, upholding one of its patents as invalid.

More on this story

Americas
22 May 2019   Merck has announced plans to acquire Peloton Therapeutics, a clinical-stage biopharmaceutical company, in a $1.05 billion bid to boost its oncology pipeline.
Big Pharma
31 October 2019   The US Court of Appeals for the Federal Circuit has delivered a blow for Merck in a patent infringement dispute against Gilead, upholding one of its patents as invalid.